Novo Nordisk A/S (NVO)
| Previous Close | 128.64 |
| Open | 127.16 |
| Bid | 125.61 x 1200 |
| Ask | 125.63 x 1000 |
| Day's Range | 125.42 - 127.32 |
| 52 Week Range | 75.56 - 138.28 |
| Volume | |
| Avg. Volume | 5,036,312 |
| Market Cap | 559.852B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 47.18 |
| EPS (TTM) | 2.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.37 (1.07%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 144.57 |
Investor's Business DailyWeight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound
Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
GlobeNewswireNovo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares a
